These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 38315144

  • 1. Pharmacokinetics and Pharmacodynamics of Etripamil, an Intranasally Administered, Fast-Acting, Nondihydropyridine Calcium Channel Blocker.
    Ip JE, Wight D, Yue CS, Nguyen D, Plat F, Stambler BS.
    Clin Pharmacol Drug Dev; 2024 Apr; 13(4):367-379. PubMed ID: 38315144
    [Abstract] [Full Text] [Related]

  • 2. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial.
    Stambler BS, Camm AJ, Alings M, Dorian P, Heidbuchel H, Houtgraaf J, Kowey PR, Merino JL, Mondésert B, Piccini JP, Pokorney SD, Sager PT, Verma A, Wharton JM, Bharucha DB, Plat F, Shardonofsky S, Chen M, Ip JE, RAPID Investigators.
    Lancet; 2023 Jul 08; 402(10396):118-128. PubMed ID: 37331368
    [Abstract] [Full Text] [Related]

  • 3. Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardia.
    Stambler BS, Plat F, Sager PT, Lubkov V, Shardonofsky S, Wight D, Chen M, Camm AJ.
    Am Heart J; 2022 Nov 08; 253():20-29. PubMed ID: 35728658
    [Abstract] [Full Text] [Related]

  • 4. First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301).
    Stambler BS, Plat F, Sager PT, Shardonofsky S, Wight D, Potvin D, Pandey AS, Ip JE, Coutu B, Mondésert B, Sterns LD, Bennett M, Anderson JL, Damle R, Haberman R, Camm AJ.
    Circ Arrhythm Electrophysiol; 2022 Dec 08; 15(12):e010915. PubMed ID: 36441560
    [Abstract] [Full Text] [Related]

  • 5. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm.
    Stambler BS, Dorian P, Sager PT, Wight D, Douville P, Potvin D, Shamszad P, Haberman RJ, Kuk RS, Lakkireddy DR, Teixeira JM, Bilchick KC, Damle RS, Bernstein RC, Lam WW, O'Neill G, Noseworthy PA, Venkatachalam KL, Coutu B, Mondésert B, Plat F.
    J Am Coll Cardiol; 2018 Jul 31; 72(5):489-497. PubMed ID: 30049309
    [Abstract] [Full Text] [Related]

  • 6. Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-Term Follow-Up: Results From the NODE-302 Study.
    Ip JE, Coutu B, Bennett MT, Pandey AS, Stambler BS, Sager P, Chen M, Shardonofsky S, Plat F, Camm AJ.
    J Am Heart Assoc; 2023 Oct 03; 12(19):e028227. PubMed ID: 37753718
    [Abstract] [Full Text] [Related]

  • 7. Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings.
    Ip JE, Bui H, Camm AJ, Coutu B, Noseworthy PA, Parody ML, Sears SF, Singh N, Uribe JA, Vyselaar J, Omodele S, Shardonofsky S, Bharucha DB, Stambler B.
    Am Heart J; 2024 Apr 03; 270():55-61. PubMed ID: 38266665
    [Abstract] [Full Text] [Related]

  • 8. Podcast on Self-administered Intranasal Etripamil for Symptomatic Paroxysmal Supraventricular Tachycardia: The RAPID Trial.
    Stambler BS, Ip JE.
    Cardiol Ther; 2023 Dec 03; 12(4):545-555. PubMed ID: 37950144
    [Abstract] [Full Text] [Related]

  • 9. Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201).
    Camm AJ, Piccini JP, Alings M, Dorian P, Gosselin G, Guertin MC, Ip JE, Kowey PR, Mondésert B, Prins FJ, Roux JF, Stambler BS, van Eck J, Al Windy N, Thermil N, Shardonofsky S, Bharucha DB, Roy D.
    Circ Arrhythm Electrophysiol; 2023 Dec 03; 16(12):639-650. PubMed ID: 37950726
    [Abstract] [Full Text] [Related]

  • 10. Etripamil nasal spray: an investigational agent for the rapid termination of paroxysmal supraventricular tachycardia (SVT).
    Kashou AH, Noseworthy PA.
    Expert Opin Investig Drugs; 2020 Jan 03; 29(1):1-4. PubMed ID: 31825681
    [Abstract] [Full Text] [Related]

  • 11. Plain language summary of the safety and effectiveness of etripamil for atrioventricular-nodal-dependent supraventricular tachycardia: the RAPID study.
    Ip JE, Stambler BS, Bharucha DB, Green A.
    Future Cardiol; 2024 Feb 03; 20(2):35-44. PubMed ID: 38385329
    [Abstract] [Full Text] [Related]

  • 12. Intranasal etripamil for rapid treatment of paroxysmal supraventricular tachycardia.
    Calvert P, Gupta D.
    Future Cardiol; 2024 Feb 03; 20(3):163-170. PubMed ID: 38717391
    [Abstract] [Full Text] [Related]

  • 13. Preclinical Safety Evaluation of Etripamil Nasal Spray in Cynomolgus Macaques (Macaca fascicularis) to Assess for Safety in Patients With Paroxysmal Supraventricular Tachycardia.
    Pion J, Lopez Mendez C, Moreau JP, Boulanger V, Wight D.
    Int J Toxicol; 2024 Feb 03; 43(5):503-510. PubMed ID: 39037331
    [Abstract] [Full Text] [Related]

  • 14. A Novel Calcium Channel Blocker: Etripamil: What is the Future of Intranasal Drug Delivery in the Treatment of Cardiac Arrhythmias?
    Weintraub S, Frishman WH.
    Cardiol Rev; 2024 Feb 03; 29(5):253-258. PubMed ID: 33060411
    [Abstract] [Full Text] [Related]

  • 15. The Efficacy and Safety of Etripamil Nasal Spray for Acute Paroxysmal Supraventricular Tachycardia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Abuelazm M, Kambalapalli S, Saleh O, Elzeftawy MA, Albakri K, Gowaily I, Abdelazeem B.
    Am J Cardiovasc Drugs; 2023 Jul 03; 23(4):379-391. PubMed ID: 37351813
    [Abstract] [Full Text] [Related]

  • 16. Etripamil: Intranasal Calcium Channel Blocker: A Novel Noninvasive Modality in the Treatment of Paroxysmal Supraventricular Tachycardia.
    Raja JM, Cave B, Jefferies JL, Khouzam RN.
    Curr Probl Cardiol; 2021 Mar 03; 46(3):100430. PubMed ID: 31279494
    [No Abstract] [Full Text] [Related]

  • 17. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
    Moore KH, Hussey EK, Shaw S, Fuseau E, Duquesnoy C, Pakes GE.
    Cephalalgia; 1997 Jun 03; 17(4):541-50. PubMed ID: 9209776
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
    Sun L, Ding L, Wang Y, Zhou W, Yan Z, Sun W, Zhang H, Ou N, Chen X.
    Drugs R D; 2012 Mar 01; 12(1):17-28. PubMed ID: 22339483
    [Abstract] [Full Text] [Related]

  • 19. First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker.
    Richard M, Kaufmann P, Kornberger R, Dingemanse J.
    Epilepsia; 2019 May 01; 60(5):968-978. PubMed ID: 31004346
    [Abstract] [Full Text] [Related]

  • 20. Update on Etripamil Nasal Spray for the At-home Treatment of Acute Paroxysmal Supraventricular Tachycardia.
    Chu GS, Gupta D.
    Heart Int; 2021 May 01; 15(1):2-6. PubMed ID: 36277324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.